Navigation
-
Fifteen Percent of ADXS11-001 Treated Cervix Cancer Patients Still Alive Three Years after Initial Dosing
-
Advaxis to Present at the Biotech Showcase(TM) Healthcare Conference
-
Advaxis Approved to Sell Approximately $300,000 Worth of Net Operating Tax Losses, Research Tax Credits
-
Advaxis Announces Phase II Trial Collaboration with the National Cancer Institute
-
Advaxis to Present at the LD MICRO Growth Conference
-
Advaxis CEO Thomas A. Moore to Present at the 8th Annual BIO Investor Forum
-
Advaxis Closes Second Company-Run Debt Financing
-
Advaxis Receives IRB Approval for Cervical Dysplasia Trial Of ADXS11-001
-
Advaxis Appoints Christopher Duignan Senior Vice President, Finance
-
Advaxis Added to Stonegate's Equity Research Universe
